Trade Ocugen, Inc. - OCGN CFD

0.7796-5.69%
The chart shows the OCGN stock price data over the last 1 day, with a current price of 0.7857, a high of 0.8095, and a low of 0.7796.
Low: 0.7796High: 0.8095
Sellers:
2.8777%
Buyers:
97.1223%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.0061
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02226 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02226%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00004 %
($0.01)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00004%
Overnight funding adjustment time22:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close0.8266
Open0.8095
1-Year Change-32.37%
Day's Range0.7796 - 0.8095

Trade Ocugen, Inc. - OCGN

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Latest shares articles

STUTTGART, GERMANY - Aug 15, 2021: Smartphone with logo of US biopharmaceutical company Ocugen Inc on screen in front of website Focus on left of phone display
Ocugen (OCGN) stock forecast: Awaiting regulatory approval
Hopes still high for US approval of Ocugen’s Covid vaccine, but is it all too little too late?
14:57, 23 March 2022
What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026
AMC stock forecast
AMC Entertainment stock forecast: record revenue, summer box office
AMC Entertainment is a US cinema operator whose latest results showed record quarterly revenue of about $1.6bn and a surprise adjusted profit, supported by a stronger summer box office. Explore third-party AMC price targets and technical analysis.
09:15, 12 November 2026
Apple near record highs: record iPhone sales, but memory costs could squeeze margins
Profits and revenues stay high for Apple while the hardware costs show signs of increase in the short-term.
10:08, 11 November 2026

User feedback and ratings

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-19
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

2025-06-29
p*******

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready